NCT05001828 - Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Myeloid Leukemia, Adult

Interventions

DRUG

ADI-PEG 20

ADI-PEG 20 in combination with venetoclax and azacitidine

Trial Locations (4)

RECRUITING

Levine Cancer Institute, Charlotte

RECRUITING

Sylvester Comprehensive Cancer Center, Miami

WITHDRAWN

Orchard Healthcare Research Inc, Skokie

RECRUITING

MD Anderson Cancer Center, Houston